Immunology of Infectious Disease News Volume 9.06 | Feb 17 2021

    0
    45

    IIDN 9.06 | Feb 17 2021

    Immunology of Infectious Disease News by STEMCELL Technologies

    Vol. 9.06 – 17 February, 2021

    TOP STORY

    Human
    Neutralizing Antibodies against SARS-CoV-2 Require Intact Fc Effector Functions for Optimal Therapeutic Protection

    Scientists defined correlates of protection of neutralizing human monoclonal antibodies in SARS-CoV-2-infected animals.
    [Cell]

    AbstractFull Article

    Breakthroughs take time. Isolating the right cells shouldn't. Learn more.

    PUBLICATIONSRanked by the impact factor of the journal

    SARS-CoV-2

    Time-Resolved
    Systems Immunology Reveals a Late Juncture Linked to Fatal COVID-19

    Investigators longitudinally assessed circulating proteins as well as 188 surface protein markers, transcriptome, and T-cell receptor sequence simultaneously in single peripheral immune cells from COVID-19 patients.
    [Cell]

    AbstractFull Article

    Post-Exposure
    Protection of SARS-CoV-2 Lethal Infected K18-hACE2 Transgenic Mice by Neutralizing Human Monoclonal Antibody

    The authors characterized and further evaluated the recently identified human monoclonal MD65 antibody for its ability to provide protection against a lethal SARS-CoV-2 infection of K18-hACE2 transgenic mice.
    [Nature Communications]

    Full Article

    Lasting
    Antibody and T Cell Responses to SARS-CoV-2 in COVID-19 Patients Three Months after Infection

    Researchers provide critical evidence that IgG, NAb, and T cell responses persisted in the majority of patients for at least three to four months after infection.
    [Nature Communications]

    Full Article

    Common Genetic Variation in Humans Impacts In Vitro
    Susceptibility to SARS-CoV-2 Infection

    Investigators applied human induced pluripotent stem cell-based models and CRISPR-engineering to explore the host genetics of SARS-CoV-2.
    [Stem Cell Reports]

    AbstractFull Article
    Graphical Abstract

    SARS-CoV-2
    Infects Human Pluripotent Stem Cell-Derived Cardiomyocytes, Impairing Electrical and Mechanical Function

    The authors observed that human PSC-cardiomyocytes (hPSC-CMs) expressed the viral receptor ACE2 and other viral processing factors, and that SARS-CoV-2 readily infected and replicated within hPSC-CMs, resulting in rapid cell death.
    [Stem Cell Reports]

    AbstractFull Article
    Graphical Abstract

    MORE IMMUNOLOGY OF INFECTIOUS DISEASE

    Structural and Biophysical Correlation of Anti-NANP Antibodies with In Vivo
    Protection against P. falciparum

    Scientists elucidated crystal structures, binding affinities and kinetics, and in vivo protection of eight anti-NANP antibodies derived from an RTS,S Phase IIa trial and encoded by three different heavy-chain germline genes.
    [Nature Communications]

    Full Article

    Mutations
    in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment

    Investigators hypothesized ICI resistance mutations in the IFNγ pathway would simultaneously render melanomas susceptible to oncolytic virus therapy.
    [Clinical Cancer Research]

    Abstract

    A
    Genetically Stable Zika Virus Vaccine Candidate Protects Mice against Virus Infection and Vertical Transmission

    The authors generated a Zika virus mutant, ZE4B-36, which combined mutations in both E glycosylation and NS4B P36.
    [npj Vaccines]

    Full Article

    HIV
    Induces Airway Basal Progenitor Cells to Adopt an Inflammatory Phenotype

    Researchers hypothesized that HIV induced the basal stem/progenitor cells to express inflammatory mediators that contributed to the pathogenesis of emphysema.
    [Scientific Reports]

    Full Article

    T
    Cell-Tropic HIV Efficiently Infects Alveolar Macrophages through Contact with Infected CD4+ T Cells

    Investigators collected alveolar macrophages by bronchoscopy performed in HIV-infected, antiretroviral therapy-naive and uninfected subjects.
    [Scientific Reports]

    Full Article

    Scientific resources to support your immunology research. Learn More!

    REVIEWS

    COVID-19 and the Human Innate Immune System

    Scientists provide a conceptual framework for the interaction of the human innate immune system with SARS-CoV-2 to link the clinical observations with experimental findings that have been made during the first year of the pandemic.
    [Cell]

    Abstract

    Cells within Cells: Rickettsiales and the Obligate Intracellular Bacterial Lifestyle

    The author provides an overview of the current state of knowledge of the biology of these bacteria and their interactions with host cells, with a focus on pathogenic species or those that are otherwise important for human health.
    [Nature Reviews Microbiology]

    Abstract

    INDUSTRY AND POLICY NEWS

    Ethics Approval Granted for Open Orphan’s COVID-19 Human Challenge Study Model

    Open Orphan plc announced the world’s first COVID-19 characterization study has received approval from a specially convened Research Ethics Committee.
    [Open Orphan plc (BusinessWire, Inc)]

    Press Release

    SCYNEXIS and Hansoh Pharma Announce Licensing Agreement and Strategic Partnership for Ibrexafungerp in Greater China

    SCYNEXIS, Inc. and Hansoh Pharmaceutical Group Company Limited announced a strategic partnership and license agreement for the development and commercialization of Ibrexafungerp for the Greater China region.
    [SCYNEXIS, Inc. (BusinessWire, Inc)]

    Press Release

    ImmunityBio and NantKwest Announce FDA Authorization to Study hAd5 T-Cell COVID-19 Vaccine for Combination of Subcutaneous, Oral and Sublingual Boost to Induce T-Cell, Mucosal, and Antibody Immunity

    ImmunityBio, Inc. and NantKwest, Inc. announced they have received FDA authorization to expand Phase I testing of a bivalent hAd5 T-cell COVID-19 vaccine.
    [ImmunityBio, Inc. (BusinessWire, Inc)]

    Press Release

    Takeda’s Maribavir Phase III Clinical Trial Met Primary Endpoint of Superiority to Conventional Antiviral Therapy in Transplant Recipients with Refractory, with or without Resistance, Cytomegalovirus Infection/Disease

    Takeda Pharmaceutical Company Limited announced new, late-breaking Phase III data from the TAK-620-303 trial, for the investigational drug TAK-620 which met its primary endpoint of superiority compared to conventional antiviral therapies in transplant recipients with refractory, with or without resistance, cytomegalovirus infection/disease.
    [Takeda Pharmaceutical Company Limited (BusinessWire, Inc)]

    Press Release

    FEATURED EVENT

    The 3rd
    UK Cellular Microbiology Network

    March 1 – 2, 2021
    Virtual


    > See All Events

    JOB OPPORTUNITIES

    Assistant
    Professor – Infectious Diseases

    University of California Merced – Merced, California, United States


    Postdoctoral Fellow – Human COVID Immunology

    Oklahoma Medical Research Foundation – Oklahoma City, Oklahoma, United States

    Postdoctoral Position – Single Cell Analysis for Bacterial Pathogen

    Helmholtz Centre for Infection Research – Würzburg, Germany

    Postdoctoral Researcher – 3D In Vitro Systems for Respiratory Bacterial Infections

    NCCR AntiResist – Basel, Switzerland

    Postdoctoral Position – M.
    tuberculosis
    Infection

    UT Health Science Center at Tyler – Tyler, Texas, United States

    > See All Jobs

    Submit an article, publication, job or event

    Brought to you by

    stemcell-logo-for newsletter-2

    Science News Immunology of Infectious Disease News
    Archives Contact Us

    Immunology of Infectious Disease News Twitter